Aptorum Group (APM) AI Stock Analysis

• Market Cap: $6.73M
• Dividend Yield: N/A
• Average Volume (3M): 69.39K
• Price to Earnings (P/E): 49.7
• Beta (1Y): 0.82
• Revenue Growth: -100.00%
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 5,346,823
• 10 Day Avg. Volume: 24,064
• 30 Day Avg. Volume: 69,387
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 68.53
• Enterprise Value/Revenue: 105.79
• Enterprise Value/Gross Profit: -411.67
• Enterprise Value/Ebitda: -11.83
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

Aptorum Group's overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns. Technical analysis indicates bearish trends, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data leaves these areas unassessed.

Aptorum Group Business Overview & Revenue Model

Company Description

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Aptorum Group generates revenue primarily through the development and commercialization of pharmaceutical products. The company engages in the research and development of novel therapeutics, which, upon reaching successful clinical trial phases and receiving regulatory approvals, are either marketed directly or licensed to larger pharmaceutical companies that handle distribution. Licensing agreements and partnerships with other biotech firms and research institutions are significant contributors to its revenue, allowing Aptorum Group to leverage external expertise and resources to enhance its drug development pipeline. Additionally, Aptorum explores revenue generation through its healthcare consumer products segment, which involves the sale of non-pharmaceutical products that align with its core focus on health and wellness.

Aptorum Group Financial Statement Overview

Summary

Aptorum Group faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. While debt management has improved slightly, the company's profitability and cash generation remain concerning. Continued operational losses and reliance on financing suggest potential liquidity risks.

Income Statement

The company shows declining revenue over the years with a significant revenue drop from 2022 to 2023. Gross profit margins are minimal, indicating challenges in covering costs. Net income remains negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet indicates a reduction in total debt over the recent years, improving the debt-to-equity ratio. However, the equity ratio has decreased due to reducing stockholders' equity, which may indicate financial distress or poor returns on equity investments.

Cash Flow

Cash flow from operations remains negative, indicating cash burn. Free cash flow is consistently negative, suggesting the company struggles to generate cash after expenses. There is some improvement in financing activities, showing reliance on external funding.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	431.38K	1.30M	1.54M	911.51K	535.17K
Gross Profit	10.57K	80.06K	81.85K	-104.00K	-259.00K
EBITDA	-9.22M	-15.62M	-18.02M	6.50M	-15.12M
Net Income	-2.83M	-9.80M	-25.05M	7.07M	-18.69M
Balance Sheet
Total Assets	20.64M	20.87M	21.91M	44.23M	23.95M
Cash, Cash Equivalents and Short-Term Investments	2.01M	1.99M	8.37M	31.88M	6.25M
Total Debt	3.28M	6.85M	217.17K	2.69M	6.47M
Total Liabilities	5.26M	13.03M	4.40M	6.08M	9.10M
Stockholders Equity	24.85M	15.71M	23.61M	41.83M	16.36M
Cash Flow
Free Cash Flow	-7.73M	-12.51M	-14.79M	-16.09M	-14.49M
Operating Cash Flow	-7.72M	-12.32M	-14.65M	-15.93M	-13.38M
Investing Cash Flow	624.77K	2.44M	16.51M	1.84M	-108.06K
Financing Cash Flow	4.09M	6.63M	2.78M	12.42M	-7.32M

Aptorum Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 0.97, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 41.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APM.

Aptorum Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	¥343.53B	10.93	-2.99%	2.55%	11.77%	-9.96%
LYRA	54 Neutral	$13.82M	―	-195.46%	―	-29.46%	2.71%
APM	41 Neutral	$6.73M	49.73	-18.56%	―	-100.00%	―
BCLI	40 Underperform	$11.81M	―	234.90%	―	―	62.35%
GTBP	34 Underperform	$7.02M	―	-538.87%	―	―	-26.02%
CDT	―	$5.68M	―		―	―	―
LIPO	―	$3.36M	―	-154.54%	―	―	―